Q1 2025 Nano-X Imaging Ltd Earnings Call Transcript
Key Points
- Nano X Imaging Ltd (NNOX) has made strategic acquisitions, such as USARAD and Zebra Medical Imaging, which have doubled revenues and transitioned Nanox.AI from a pre-revenue business to one generating growing revenue.
- The company has seen a significant increase in its sales pipeline, doubling since January 2025, with over 1,000 leads being handled by the sales team.
- Nano X Imaging Ltd (NNOX) has achieved regulatory success, including receiving 510(k) clearance from the FDA for the Nanox.ARC-X system.
- The company is experiencing steady revenue growth from its US teleradiology business and increasing revenues from AI solutions.
- Nano X Imaging Ltd (NNOX) is expanding its global presence, with plans to deploy over 100 ARC systems worldwide by the end of 2025, including in the US, Europe, and other regions.
- The company reported a GAAP net loss of $13.2 million for Q1 2025, an increase from the $12.2 million loss in Q1 2024.
- Despite the deployment of over 60 units, revenue inflection from these units has been slower than anticipated due to regulatory and setup delays.
- The gross loss for the reported period was $3.0 million on a GAAP basis, compared to a gross loss of $2.1 million in the comparable period.
- The AI solutions business reported a gross loss of $1.9 million on a GAAP basis for the reported period.
- The company faces challenges in introducing new and innovative technology in the US market, which requires significant time and resources for customer education and regulatory approvals.
Good day, and thank you for standing by. Welcome to the Nano-X Q1 2025 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Cavanaugh of Investor Relations. Please go ahead.
Good morning, and thank you for joining us today. Earlier today, Nano-X Imaging Limited released financial results for the quarter ended March 31, 2025. The release is currently available on the Investors section of the company's website. With me today are Erez Meltzer, Chief Executive Officer and acting Chairman, and Ran Daniel, Chief Financial Officer.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing and commercialization activities, regulatory process and clinical activities, and other matters. These statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
